The PRSER+ and PRSPC odds ratios with breast or prostate cancer risks appeared to be larger for class II variant (pathogenic variants likely to yield stable mutant proteins) carriers compared with class I BRCA1 and BRCA2 variant carriers (Table 3). This evidence concerns the gene BRCA1 and Familial prostate cancer.